Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18360420 | 1.00 | BTK (0.60) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL19719164 | 1.00 | BTK (0.60) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL18338559 | 1.00 | BTK (0.60) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL21377005 | 1.00 | BTK (0.60) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL14169340 | 0.93 | ALDH1A1 (0.58) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL20625306 | 0.92 | ALDH1A1 (0.58) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL31333590 | 0.91 | ALDH1A1 (0.56) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL31333924 | 0.91 | ALDH1A1 (0.56) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL2670623 | 0.90 | KMT2A (0.63) | BTKKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL6370475 | 0.90 | KMT2A (0.63) | BTKKMT2AL3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20220340592-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2022-10-27 | — | — | US | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| WO-2021227904-A1 | POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| EP-3539961-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| CN-107873028-B | Polycyclic amide derivatives useful as CDK9 inhibitors | 阿斯利康(瑞典)有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10717746-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-07-21 | — | — | US | disclosed |
| EP-3539961-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | Astrazeneca AB (SE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3313838-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| US-20160376287-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340592-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | BTK 398/4885KMT2A 138/4885L3MBTL1 1489/4885 |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | BTK 398/4885KMT2A 138/4885L3MBTL1 1489/4885 |
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | CDK9, CDK8, CDK19 | BTK 753/4885KMT2A 93/4885L3MBTL1 987/4885 |
| US-20160376287-A1 | Chemical Compounds | CDK9, BCL9, BCL9L | BTK 398/4885KMT2A 138/4885L3MBTL1 1489/4885 |
| US-10717746-B2 | Chemical compounds | CDK9, BCL9, BCL9L | BTK 398/4885KMT2A 138/4885L3MBTL1 1489/4885 |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | BTK 398/4885KMT2A 138/4885L3MBTL1 1489/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | BTK 291/4885KMT2A 236/4885L3MBTL1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.